AzTrials
AzTrials

Atrial FibrillationPhase 3ELIMINATE-AFNCT02942576

Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation

A Phase 3 study testing Edoxaban and VKA-Based Regimen in people with Atrial Fibrillation, run by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company at 75 sites in 11 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

There are insufficient data on the safety and efficacy of edoxaban therapy in subjects with AF following catheter ablation. This phase 3b study is designed to evaluate the safety and to explore the efficacy of an edoxaban-based antithrombotic regimen versus a VKA-based antithrombotic regimen in subjects with AF… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Atrial Fibrillation
What is being tested?
Edoxaban and VKA-Based Regimen
Could I receive a placebo?
No, everyone receives an active treatment
How many people
632 participants
Where
75 sitesin 11 countries
Study dates
21 Mar 2017to 24 Sep 2018
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female at least 18 years of age with documented history of paroxysmal (lasting ≤7 days), persistent (lasting >7 days but ≤12 months) or long-standing [long-lasting] persistent (>12 months) non-valvular AF. Duration of AF can be confirmed by any electrical tracing or a recording in the subject's medical records (e.g., medical chart, hospital discharge summary).
  • Subject is eligible and is scheduled for either radio frequency (RF) or cryoballoon catheter ablation (both first and repeated procedure included).
  • Signed informed consent form (ICF).

Who cannot join

  • AF considered to be of a transient or reversible nature (such as in myocarditis, post-surgery, ionic disturbances, thyrotoxicosis, pneumonia, severe anemia etc.).
  • Subject post stroke, or with a systemic thromboembolic event within the past 6 months prior to randomization.
  • Subject has a thrombus in the left atrial appendage (LAA), left atrium (LA), left ventricle (LV), or aorta, or an intracardial mass.
  • Subject had a myocardial infarction (MI) within the 2 months prior to randomization or coronary artery bypass graft (CABG) surgery within 3 months prior to the randomization.
  • Subject has signs of bleeding, history of clinically-relevant bleeding according to International Society on Thrombosis and Hemostasis (ISTH), or conditions associated with high risk of bleeding
  • Subjects with any contraindication for anticoagulant agents.

Trial locations and contacts

75 sites in 11 countries.

75 sites in 11 countries

Germany14 sites

  • Universitäts Herzzentrum Freiburg-Bad Krozingen Klinik für Kardiologie und Angiologie II

    Bad Krozingen, 79189

  • Charité Universitätsmedizin Berlin - CVK Medizinische Klinik m.S. Kardiologie

    Berlin, 13353

  • Klinikum Bielefeld Klinik für Kardiologie/internist. Intensivmedizin

    Bielefeld, 33604

  • Klinikum Coburg GmbH II.Med.Klinik

    Coburg, 96450

  • Klinik für Innere Medizin I

    Dortmund, 44137

  • University Clinic Duesseldorf Clinic for Cardiology, Pneumology and Angiology

    Düsseldorf, 40225

  • Universitäres Herzzentrum Hamburg Kardiologie mit Schwerpunkt Elektrophysiologie

    Hamburg, 20251

  • University Hospital of Heidelberg Clinic of Cardiology, Angiology and Pneumology

    Heidelberg, 69120

  • Herzzentrum Leipzig - Universitätsklinik Abteilung für Rhythmologie

    Leipzig, 04289

  • Univ. of Muenster.Cardiovascular Medicine

    Münster, 48149

  • Universitätsmedizin Rostock Zentrum für Innere Medizin I, Kardiologie

    Rostock, 18057

  • Deutsches Herzk. Universitätsklinikum Tübingen Medizinische Klinik III. Kardiologie

    Tübingen, 72076

  • Universitätsklinikum Ulm

    Ulm, 89081

  • Universitätsklinikum Würzburg Medizinische Klinik und Poliklinik I

    Würzburg, 97080

Other trials in Germany

Italy14 sites

  • Ospedale San Donato

    Arezzo, 52100

  • Pineta Grande Hospital

    Castel Volturno, 81030

  • Universita' degli Studi Catanzaro

    Catanzaro, 88100

  • Arcispedale Sant'Anna

    Cona, 44124

  • Azienda USL Toscana

    Florence, 50122

  • Ospedale della Misericordia

    Grosseto, 58100

  • Ospedale dell'Angelo

    Mestre, 30174

  • ASST Vimercate

    Monza, 80082

  • Ospedale Santo Cuore

    Negrar, 37024

  • Istituto di Cura cittè di Pavia

    Pavia, 27100

  • Azienda Ospedaliera di Piacenza "Ospedale Guglielmo d Saliceto"

    Piacenza, 29124

  • Policlinico Casilino

    Roma, 00169

  • Largo Agostino Gemelli

    Rome, 00168

  • Ospedale Ecclesiastico "Miulli"

    Sant'Eramo, 70021

Other trials in Italy

Czechia7 sites

  • FN Brno

    Brno, 625 00

  • St. Anne's University Hospital Brno, International Clinical Research Center

    Brno, 69691

  • FN Kralovske Vinohrady

    Prague, 100 34

  • VFN v Praze II. Interní klinika - Kardiologie a angiologie

    Prague, 128 08

  • IKEM

    Prague, 14021

  • University Hospital Motol - Cardiology

    Prague, 150 06

  • Masarykova nemocnice - Kardiologie Krajská zdravotní, a.s.

    Ústí nad Labem, 40113

Other trials in Czechia

Hungary6 sites

  • Semmelweis Egyetem Városmajori Szív- és Érgyógyászati Klinika

    Budapest, 1122

  • Magyar Honvédség Egészségügyi Központ Kardiológiai Osztály

    Budapest, 1134

  • Debreceni Egyetem Kardiológiai és Szívsebészeti Klinika

    Debrecen, 4032

  • Pecs University Clinical Center

    Pécs, H 7624

  • Szegedi Tudományegyetem II. Belgyógyászati Klnika és Kardiológiai Központ

    Szeged, 6725

  • Zala Megyei Szent Rafael Kórház Kardiológia Osztály

    Zalaegerszeg, 8900

Other trials in Hungary

United Kingdom6 sites

  • Blackpool Teaching Hospitals NHS

    Blackpool, FY3 8NR

  • Royal Bournemouth Hospital

    Bournemouth, BH7 7DW

  • Papworth Hospital NHS Trust

    Cambridge, CB23 3RE

  • Leeds General Infirmary

    Leeds, LS1 3EX

  • King's College Hospital

    London, SE5 9RS

  • Nottingham City Hospital

    Nottingham, NG5 1PB

Other trials in United Kingdom

Poland5 sites

  • University Hospital - Szpital Uniwersytecki

    Krakow, 31-501

  • Klinika Intensywnej Terapii Kardiologicznej

    Lodz, 92-213

  • Samodzielny Publiczny Szpital Kliniczny Nr 4 Klinika Kardiologii

    Lublin, 20-954

  • Oddzial Kardiologii Szpital Grochowski im. dr R. Masztaka SPZOZ

    Warsaw, 04-073

  • Oddział Kliniczny Kardiologii SUM Katedra Kardiologii

    Zabrze, 41-800

Other trials in Poland

South Korea5 sites

  • Samsung Medical Center

    Seoul, Gangnam-gu, 06351

  • Seoul National University Hospital

    Seoul, Jongno-gu, 03080

  • Yonsei University Severance Hospital

    Seoul, Seodaemun-Gu, 03722

  • Korea University Anam Hospital

    Seoul, Seoungbuk-gu, 02841

  • Asan Medical Center

    Seoul, 138-736

Other trials in South Korea

Spain5 sites

  • Hospital General Universitario

    Alicante, 03540

  • Hospital del Mar

    Barcelona, 08003

  • Hospital Clinic Cardiologia

    Barcelona, 8036

  • Fundacion Jimenez Diaz

    Madrid, 28040

  • Hospital Universitario San Juan de Alicante

    Sant Joan d'Alacant, 03550

Other trials in Spain

Taiwan5 sites

  • Chang Gung Memorial Hospital

    Kaohsiung City, 83301

  • China Medical University Hospital

    Taichung, 40447

  • Taichung Veterans General Hospital (VGH-TC)

    Taichung, 40705

  • Taipei Veterans General Hospital

    Taipei, 112

  • Chang Gung Memorial Hospital

    Taoyuan City, 33305

Other trials in Taiwan

Belgium4 sites

  • ZNA Middelheim

    Antwerp, 2020

  • Erasme Hospital

    Brussels, 1070

  • UZ Brussel

    Brussels, 1090

  • Universitair Ziekenhuis Antwerpen

    Edegem, 2650

Other trials in Belgium

Canada4 sites

  • University of Calgary

    Calgary, T2N 4Z6

  • Hamilton Health Sciences/McMaster University

    Hamilton, L8L 2X2

  • Montreal Heart Institute

    Montreal, H1T 1C8

  • Centre Hospitalier Universitaire de Sherbrooke

    Sherbrooke, J1H 5N4

Other trials in Canada

About this study

Official title: A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation (ELIMINATE-AF)

There are insufficient data on the safety and efficacy of edoxaban therapy in subjects with AF following catheter ablation. This phase 3b study is designed to evaluate the safety and to explore the efficacy of an edoxaban-based antithrombotic regimen versus a VKA-based antithrombotic regimen in subjects with AF following catheter ablation. Bleeding is a central safety outcome in cardiovascular clinical trials, especially for antithrombotic strategies and invasive procedures.

Being tested
Edoxaban, VKA-Based Regimen
Medical subject headings
Atrial Fibrillation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • EdoxabanDrug

    Also called Lixiana

    Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects.

  • VKA-Based RegimenDrug

    Also called Warfarin

    Dosed at International Normalised Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in Canada, Italy, Poland, Hungary, Czech Republic, United Kingdom (UK), Taiwan and Korea.

  • VKA-Based RegimenDrug

    Also called Phenprogamma, Phenprocoumon

    Dosed at INR levels. Standard of Care treatment in Germany, Belgium, and the Netherlands.

  • VKA-Based RegimenDrug

    Also called Previscan, Fluindione

    Dosed at INR levels. Standard of Care treatment in France.

  • VKA-Based RegimenDrug

    Also called Sintrom, Acenocoumarol

    Dosed at INR levels. Standard of Care treatment in Spain.

Study groups in NCT02942576
Study groupRoleWhat they receive
Edoxaban-based regimenExperimentalEdoxaban-based regimen for 21 days pre- and 90 days post-ablation period.
Receives: Drug: Edoxaban
VKA-based regimenActive comparatorVKA-based regimen for 21 days pre- and 90 days post-ablation period (control regimen)
Receives: Drug: VKA-Based Regimen

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants Who Experienced the Composite of All-cause Death, Stroke (VARC-2), and Major Bleeding (ISTH) in the Edoxaban Group Compared With Vitamin K Antagonist (VKA) Group in Participants Undergoing Catheter Ablation (Adjudicated Data)

    Stroke (ischemic, hemorrhagic, or undetermined) was defined by Valve Academic Research Consortium-2 (VARC-2) as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury following hemorrhage or infarction. A stroke event was based on any of the following: duration of neurological dysfunction >24 hours (h), duration of neurological dysfunction <24 h in case of imaging-documented new hemorrhage or infarction, and a neurological dysfunction resulting in death.

    Major bleeding was defined by the International Society on Thrombosis and Hemostasis (ISTH) as fatal bleeding and/or bleeding that is symptomatic and occurs in a critical area or organ and/or extrasurgical site bleeding causing a fall in hemoglobin level of >2 g/dL or leads to blood transfusion, surgical site bleeding that requires a second intervention, causes hemarthrosis that delays mobilization or wound healing, or causes hemodynamic instability.

    Measured: Day 1 to Day 90

  2. Number of Participants Who Experienced Major Bleeding (International Society on Thrombosis and Hemostasis [ISTH]) in the Edoxaban Group Compared With VKA Group Among Participants Undergoing Catheter Ablation (Adjudicated Data)

    Major bleeding was defined by the International Society on Thrombosis and Hemostasis (ISTH) as fatal bleeding and/or bleeding that is symptomatic and occurs in a critical area or organ and/or extrasurgical site bleeding causing a fall in hemoglobin level of >2 g/dL or leads to blood transfusion, surgical site bleeding that requires a second intervention, causes hemarthrosis that delays mobilization or wound healing, or causes hemodynamic instability.

    Measured: Day 1 to Day 90

Secondary outcomes (2)

  1. Number of Participants Who Experienced the Composite of All-cause Death, Stroke (Alternative), and Major Bleeding (ISTH) in the Edoxaban Group Compared With VKA Group Among Participants Undergoing Catheter Ablation (Adjudicated Data)

    An alternative definition characterized stroke (ischemic, hemorrhagic, or undetermined) as an abrupt onset, over minutes to hours, of a focal neurological deficit in the distribution of a single brain artery that was not due to an identifiable nonvascular cause (ie, brain tumor or trauma), and that either lasted at least 24 hours or resulted in death within 24 hours of onset.

    Major bleeding was defined by the International Society on Thrombosis and Hemostasis (ISTH) as fatal bleeding and/or bleeding that is symptomatic and occurs in a critical area or organ and/or extrasurgical site bleeding causing a fall in hemoglobin level of >2 g/dL or leads to blood transfusion, surgical site bleeding that requires a second intervention, causes hemarthrosis that delays mobilization or wound healing, or causes hemodynamic instability.

    Measured: Day 1 to Day 90

  2. Number of Participants Who Experienced the Composite of Stroke (VARC-2), Systemic Embolic Events (SEE), and Cardiovascular (CV) Mortality in the Edoxaban Group Compared With VKA Group Among Participants Undergoing Catheter Ablation (Adjudicated Data)

    Stroke (ischemic, hemorrhagic, or undetermined) was defined by Valve Academic Research Consortium-2 (VARC-2) as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury following hemorrhage or infarction. A stroke event was based on any of the following: duration of neurological dysfunction >24 hours (h), duration of neurological dysfunction <24 h in case of imaging-documented new hemorrhage or infarction, and a neurological dysfunction resulting in death.

    SEE was defined as an arterial embolism resulting in clinical ischemia, excluding the central nervous system, coronary, and pulmonary arterial circulation.

    CV mortality was defined as cardiac or vascular death according to Academic Research Consortium.

    Measured: Day 1 to Day 90

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Oct 2016 (estimated)
  2. Study start21 Mar 2017
  3. Primary completion24 Sep 2018
  4. Study completion24 Sep 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
632 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02942576
Sponsor's protocol ID
DSE-EDO-01-16-EU
Other IDs
2016-003069-25, 2016
Acronym
ELIMINATE-AF
Status last verified
Aug 2019
First submitted
21 Oct 2016
Last updated
23 Sep 2019
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Publications

  • Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19.

    PubMed 24251359

  • Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016 Nov;18(11):1609-1678. doi: 10.1093/europace/euw295. Epub 2016 Aug 27. No abstract available.

    PubMed 27567465

  • Crawford T, Oral H. Current status and outcomes of catheter ablation for atrial fibrillation. Heart Rhythm. 2009 Dec;6(12 Suppl):S12-7. doi: 10.1016/j.hrthm.2009.07.026. Epub 2009 Oct 23.

    PubMed 19864188

  • Hussein AA, Martin DO, Saliba W, Patel D, Karim S, Batal O, Banna M, Williams-Andrews M, Sherman M, Kanj M, Bhargava M, Dresing T, Callahan T, Tchou P, Di Biase L, Beheiry S, Lindsay B, Natale A, Wazni O. Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm. 2009 Oct;6(10):1425-9. doi: 10.1016/j.hrthm.2009.07.007. Epub 2009 Jul 10.

    PubMed 19968920

  • Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ, Ma CS, Hess S, Wells DS, Juang G, Vijgen J, Hugl BJ, Balasubramaniam R, De Chillou C, Davies DW, Fields LE, Natale A; VENTURE-AF Investigators. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015 Jul 21;36(28):1805-11. doi: 10.1093/eurheartj/ehv177. Epub 2015 May 14.

    PubMed 25975659

  • Chen J, Todd DM, Hocini M, Larsen TB, Bongiorni MG, Blomstrom-Lundqvist C; Scientific Initiative Committee, European Heart Rhythm Association. Current periprocedural management of ablation for atrial fibrillation in Europe: results of the European Heart Rhythm Association survey. Europace. 2014 Mar;16(3):378-81. doi: 10.1093/europace/euu043.

    PubMed 24569891

  • Hokusai-VTE Investigators; Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31.

    PubMed 23991658

  • Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein G, Natale A, Packer D, Skanes A, Ambrogi F, Biganzoli E. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010 Feb;3(1):32-8. doi: 10.1161/CIRCEP.109.859116. Epub 2009 Dec 7.

    PubMed 19995881

  • Hohnloser SH, Camm AJ, Cappato R, Diener HC, Heidbuchel H, Mont L, Morillo CA, Lanz HJ, Rauer H, Reimitz PE, Smolnik R, Kautzner J. Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial. Europace. 2021 Jan 27;23(1):65-72. doi: 10.1093/europace/euaa199.

    PubMed 33249467

  • Hohnloser SH, Camm J, Cappato R, Diener HC, Heidbuchel H, Lanz HJ, Mont L, Morillo CA, Smolnik R, Yin OQP, Kautzner J. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study. Clin Cardiol. 2018 Apr;41(4):440-449. doi: 10.1002/clc.22918. Epub 2018 Apr 17.

    PubMed 29663464

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Edoxaban and VKA-Based Regimen in people with Atrial Fibrillation, run by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company at 75 sites in 11 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 75 sites in Germany, Italy, Czechia, Hungary, United Kingdom and 6 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 23 Sep 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants Who Experienced the Composite of All-cause Death, Stroke (VARC-2), and Major Bleeding (ISTH) in the Edoxaban Group Compared With Vitamin K Antagonist (VKA) Group in Participants Undergoing Catheter Ablation (Adjudicated Data) (time frame: Day 1 to Day 90). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02942576, which also lists 10 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2019.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in